Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Impedimed Limited ( (AU:IPD) ) just unveiled an update.
Impedimed Limited announced the issuance of 700,244 ordinary fully paid shares to executives as part of their remuneration under the Executive Share Plan for the quarter ended December 31, 2024. This move could potentially align executive interests with company performance, thus impacting company operations and possibly influencing investor perception positively.
More about Impedimed Limited
Impedimed Limited operates within the medical technology industry, providing non-invasive medical products focused on the measurement and monitoring of fluid status and tissue composition.
YTD Price Performance: -2.50%
Average Trading Volume: 31,879
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $69.19M
Find detailed analytics on IPD stock on TipRanks’ Stock Analysis page.
